Carcinoid Syndrome
Conditions
Keywords
Carcinoid tumor, Somatuline Depot, Lanreotide Autogel, Neuroendocrine tumor, NET, Diarrhea, Flushing, Carcinoid tumour, Neuroendocrine tumour, Diarrhoea
Brief summary
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.
Detailed description
This study consisted of a Screening period, conducted up to 4 months before randomisation, followed by three phases: a 16-week, double blind (DB), randomised, placebo-controlled phase; a 32-week initial open label (IOL) phase; and a long term open label extension (LTOLE) phase. The DB phase evaluated lanreotide Autogel versus placebo in subjects with a history of carcinoid syndrome (flushing and/or diarrhoea). This was followed by a 32-week IOL phase in which all subjects received lanreotide Autogel 120 mg every 4 weeks. Subjects in countries where lanreotide Autogel had not been approved for the treatment of carcinoid syndrome, who were well-controlled at the end of the 32-week IOL phase and chose to continue to receive lanreotide Autogel, were given the option of participating in a LTOLE phase. The LTOLE phase of the study was planned to end at least 2 years after the last subject had completed his/her participation in the 32-week IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome had been obtained in the respective countries (whichever occurred first) or at any time the study was terminated by the Sponsor. The actual overall duration of the study was 6.5 years. During the LTOLE phase all subjects continued to be treated with lanreotide Autogel 120 mg every 4 weeks. The study planned to enrol approximately 100 adult subjects worldwide. Screening continued until 115 subjects were enrolled in the study.
Interventions
DRUGLanreotide
deep s.c. injection, 120 mg, every 4 weeks (±3 days).
DRUGPlacebo
deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
Sponsors
Ipsen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects were eligible for participation in the study if they met the following criteria: 1. At least 18 years of age at the time of first dosing. 2. Subjects must have given signed informed consent before any study related activities were conducted. 3. Subjects in the United States of America (USA) must have given written authorisation for the release of protected health information in compliance with the Health Insurance Portability and Accountability Act (HIPAA) regulations; subjects in other countries must have provided appropriate authorisation as needed by regulatory authorities in each country. 4. Subjects must have been willing to receive s.c. octreotide injections as rescue medication, as needed to control their symptoms, if any. 5. If female, the subject must not have been pregnant (confirmed by negative pregnancy test) and must have had the following documented via verbally given history: * At least 1 year postmenopausal (natural cessation of menses), or * Surgically sterile (if by tubal ligation, surgery must have been performed more than 3 months prior to entry into the study), or * If the subject was of childbearing potential and sexually active, she must have been using an acceptable form of contraception (oral, injected, transdermal or implanted contraceptives, diaphragm or barrier method with spermicidal and/or intrauterine device); local methods such as condoms or sponges/vaginal tablets were not acceptable forms of contraception. 6. Subjects with a histopathologically confirmed diagnosis of carcinoid tumour or, a carcinoid tumour of unknown location with liver metastases (documented biopsy), and a history of carcinoid syndrome (flushing and/or diarrhoea) who were either naïve to treatment with a somatostatin analogue (SSTa) or responsive (according to the opinion of the principal investigator) to conventional doses of Sandostatin LAR® Depot (LAR; ≤30 mg every 4 weeks) or to daily doses of ≤600 μg of s.c. octreotide. 7. Confirmation of positive somatostatin receptor (SSTR) status by somatostatin receptor scintigraphy (SRS; up to 6 months prior to study entry at the Screening Visit). 8. Absence of tumour progression documented by two sequential computed tomography (CT) scans or two sequential magnetic resonance imaging (MRI) scans (≥3 months apart); the last CT or MRI scan must have been performed within 6 months of study entry (Screening Visit). 9. Subjects previously treated with LAR, must have received their last dose of LAR at least 4 weeks prior to first dose of study treatment (no later than at the Screening Visit). 10. Be able to communicate and cooperate with the principal investigator and the staff and willing to comply with the study instructions. Subjects were excluded from entering the study for the following reasons: 1. History of known allergy or hypersensitivity to investigational drug or any components of its formulation, or octreotide. 2. History of carcinoid syndrome refractory to treatment with conventional doses of SSTa. 3. Treatment with any other investigational drug within 30 days prior to study entry (Screening Visit) and/or at any time during the subject's participation in the study. 4. Treatment with interferon, chemotherapy and/or radiotherapy (a radiolabelled SSTa) and/or tumour debulking \<3 months prior to study entry (Screening Visit). 5. History of hepatic arterial embolisation, hepatic arterial chemoembolisation and/or selective internal radiation therapy (selective internal radiation \[SIR\] therapy \[SIRT\]; e.g. SIR Spheres) \<6 months prior to study entry (Screening Visit). 6. Short bowel syndrome. 7. Uncontrolled diabetes and/or hypertension. 8. Severe renal impairment (glomerular filtration rate \<30 mL/min/1.73 m2) and/or severe liver impairment as evidenced by serum total bilirubin \>1.5 mg/dL associated with bile duct blockage or with alkaline phosphatase (ALP), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>5.0 upper limit of normal (ULN). 9. Diagnosis of cardiac disease New York Heart Association (NYHA) functional classification \>Class I. (Subject has limitation of physical activity. Ordinary physical activity causes undue fatigue, palpitation, or dyspnoea). 10. Life expectancy less than 1 year. 11. Any malignancies except carcinoid tumour, basocellular carcinoma of the skin, in situ carcinoma of the cervix and ≥5 years disease free after curative cancer treatment. 12. Any serious medical condition that could jeopardise the safety of the subject and/or the efficacy assessments of the study. 13. Subject is being treated with a proton pump inhibitor (PPI) and has been at a stable dose (no change in dose or frequency of administration) for less than 4 weeks at study entry (Screening Visit).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Days With Subcutaneous Octreotide as Rescue Medication | 16-week DB phase | Use of s.c. octreotide required to control symptoms associated with carcinoid syndrome, measured as the percentage of days that s.c. octreotide was used as rescue medication, based on subject Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS) diary records. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records. | 16-week DB phase | — |
| Percentage of Days of Use of Other Rescue Medication | 16-week DB phase | Usage of other concomitant rescue medications for diarrhoea and/or flushing events, measured as the percentage of days that the medications were used as rescue medication based on subject IVRS/IWRS diary records. Subjects were required to record the use and dose of s.c. octreotide, if any, as well as the use of other concomitant rescue medications (e.g. loperamide 2 mg tabs, and/or tincture of opium). |
| Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study | 16-week DB phase | Subjects who rolled over early were those who received less than four DB injections before receiving the first IOL injection. |
| Changes From Baseline in Global Health Status/Quality of Life (QoL) Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30) | Baseline and Week 12 of DB phase | Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. Q29 and Q30 range from 1 (Very poor) to 7 (Excellent) with 1 being worst case and 7 the most favourable answer. Scores were derived according to the rules contained within the EORTC scoring manual. All of the scores range in score from 0 to 100. A high score for global health status/QoL represents high QoL. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. Raw score = RS = (I1 + I2 +…+ In)/n. For global health status/QoL: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS. |
| Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records. | 16-week DB phase | — |
| Changes From Baseline in QoL in Endocrine Symptoms Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires) | Baseline and Week 12 of DB phase | Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n. For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS. |
| Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA]) | Baseline and Week 12 of DB phase | Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. |
| Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA]) | Baseline and Week 12 of DB phase | Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. |
| Changes From Baseline in Gastrointestinal (G.I). Symptoms Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21] | Baseline and Week 12 of DB phase | Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n. For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS. |
Countries
Brazil, Czechia, India, Latvia, Poland, Russia, Serbia, South Africa, Turkey (Türkiye), Ukraine, United States
Participant flow
Recruitment details
Subjects were recruited from multiple sites across countries from May 2009. The study was completed in December 2015.
Pre-assignment details
A total of 153 subjects were screened; 115 were randomized and 38 failed screening.
Participants by arm
| Arm | Count |
|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase. Intent-to-treat (ITT) population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group. | 59 |
| Placebo Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase. | 56 |
| Total | 115 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| DB Phase | Adverse Event | 1 | 2 |
| DB Phase | Disease Progression | 1 | 1 |
| DB Phase | Early Roll Over (ERO) to IOL phase | 11 | 12 |
| DB Phase | Sponsor Decision | 0 | 1 |
| DB Phase | Started Nonprotocol Radiation therapy | 0 | 1 |
| DB Phase | Subject Decision | 1 | 5 |
| IOL Phase | Adverse Event | 1 | 1 |
| IOL Phase | Brain radiation | 0 | 1 |
| IOL Phase | Disease Progression | 2 | 1 |
| IOL Phase | Other | 1 | 0 |
| IOL Phase | Peptide Receptor Radionuclide Therapy | 0 | 1 |
| IOL Phase | Physician Decision | 3 | 2 |
| IOL Phase | Sponsor Decision | 1 | 0 |
| IOL Phase | Subject Consumed Prohibited Medication | 1 | 0 |
| IOL Phase | Subject Decision | 4 | 3 |
| LTOLE Phase | Adverse Event | 7 | 3 |
| LTOLE Phase | Disease Progression | 2 | 5 |
| LTOLE Phase | Physician Decision | 4 | 1 |
| LTOLE Phase | Proton Pump Inhibitor Dose Adjusted | 0 | 1 |
| LTOLE Phase | Sponsor decision | 2 | 1 |
| LTOLE Phase | Subject decision | 0 | 5 |
| LTOLE Phase | Tumour Progression of Hepatic Metastases | 0 | 1 |
Baseline characteristics
| Characteristic | Lanreotide Autogel (Somatuline Depot) 120 mg | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 57.9 years STANDARD_DEVIATION 10.6 | 58.6 years STANDARD_DEVIATION 11.1 | 59.3 years STANDARD_DEVIATION 11.6 |
| Race/Ethnicity, Customized Asian | 6 participants | 9 participants | 3 participants |
| Race/Ethnicity, Customized Black/African American | 2 participants | 5 participants | 3 participants |
| Race/Ethnicity, Customized Multi race | 7 participants | 13 participants | 6 participants |
| Race/Ethnicity, Customized White | 44 participants | 88 participants | 44 participants |
| Sex: Female, Male Female | 32 Participants | 67 Participants | 35 Participants |
| Sex: Female, Male Male | 27 Participants | 48 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 31 / 58 | 34 / 57 | 71 / 101 | 46 / 57 |
| serious Total, serious adverse events | 2 / 58 | 5 / 57 | 8 / 101 | 15 / 57 |
Outcome results
Primary
Percentage of Days With Subcutaneous Octreotide as Rescue Medication
Use of s.c. octreotide required to control symptoms associated with carcinoid syndrome, measured as the percentage of days that s.c. octreotide was used as rescue medication, based on subject Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS) diary records.
Time frame: 16-week DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Percentage of Days With Subcutaneous Octreotide as Rescue Medication | 33.72 Percentage of days |
| Placebo | Percentage of Days With Subcutaneous Octreotide as Rescue Medication | 48.49 Percentage of days |
p-value: 0.0165ANCOVA
Secondary
Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA])
Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
Time frame: Baseline and Week 12 of DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA]) | 1125.8 μg/L | Standard Deviation 12579.4 |
| Placebo | Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA]) | 801.5 μg/L | Standard Deviation 2294 |
Secondary
Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA])
Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
Time frame: Baseline and Week 12 of DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA]) | -201.4 μmol/day | Standard Deviation 1009.9 |
| Placebo | Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA]) | 36.3 μmol/day | Standard Deviation 142.3 |
Secondary
Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.
Time frame: 16-week DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records. | 1.56 Number of events per day | Standard Deviation 1.83 |
| Placebo | Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records. | 1.35 Number of events per day | Standard Deviation 1.45 |
p-value: 0.2544ANCOVA
Secondary
Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.
Time frame: 16-week DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records. | 0.92 Number of events per day | Standard Deviation 1.45 |
| Placebo | Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records. | 1.75 Number of events per day | Standard Deviation 2.26 |
Secondary
Changes From Baseline in Gastrointestinal (G.I). Symptoms Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]
Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n. For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.
Time frame: Baseline and Week 12 of DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Changes From Baseline in Gastrointestinal (G.I). Symptoms Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21] | -4.06 Units on a scale | Standard Deviation 12.8 |
| Placebo | Changes From Baseline in Gastrointestinal (G.I). Symptoms Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21] | 0.10 Units on a scale | Standard Deviation 13.83 |
Secondary
Changes From Baseline in Global Health Status/Quality of Life (QoL) Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)
Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. Q29 and Q30 range from 1 (Very poor) to 7 (Excellent) with 1 being worst case and 7 the most favourable answer. Scores were derived according to the rules contained within the EORTC scoring manual. All of the scores range in score from 0 to 100. A high score for global health status/QoL represents high QoL. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. Raw score = RS = (I1 + I2 +…+ In)/n. For global health status/QoL: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.
Time frame: Baseline and Week 12 of DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Changes From Baseline in Global Health Status/Quality of Life (QoL) Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30) | 4.17 Units on a scale | Standard Deviation 14.18 |
| Placebo | Changes From Baseline in Global Health Status/Quality of Life (QoL) Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30) | -1.72 Units on a scale | Standard Deviation 18.21 |
Secondary
Changes From Baseline in QoL in Endocrine Symptoms Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)
Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n. For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.
Time frame: Baseline and Week 12 of DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Changes From Baseline in QoL in Endocrine Symptoms Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires) | -6.83 Units on a scale | Standard Deviation 18.98 |
| Placebo | Changes From Baseline in QoL in Endocrine Symptoms Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires) | -2.69 Units on a scale | Standard Deviation 22.23 |
Secondary
Percentage of Days of Use of Other Rescue Medication
Usage of other concomitant rescue medications for diarrhoea and/or flushing events, measured as the percentage of days that the medications were used as rescue medication based on subject IVRS/IWRS diary records. Subjects were required to record the use and dose of s.c. octreotide, if any, as well as the use of other concomitant rescue medications (e.g. loperamide 2 mg tabs, and/or tincture of opium).
Time frame: 16-week DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Percentage of Days of Use of Other Rescue Medication | 8.86 Percentage of days | Standard Deviation 19.34 |
| Placebo | Percentage of Days of Use of Other Rescue Medication | 6.25 Percentage of days | Standard Deviation 17.48 |
Secondary
Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study
Subjects who rolled over early were those who received less than four DB injections before receiving the first IOL injection.
Time frame: 16-week DB phase
Population: ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lanreotide Autogel (Somatuline Depot) 120 mg | Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study | 18.6 Percentage of subjects |
| Placebo | Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study | 21.4 Percentage of subjects |